ABSTRACT
INTRODUCTION
Prostagladins have an inhibitory effect on testicular steroidogenesis and spermatogenesis in vivo, as well as on sperm motility in vitro. These observations suggest a negative regulatory effect of prostoglandins on testicular and spermatozoal function and conclude a potential beneficial effect of prostaglandin inhibition on fertility. Statistical correlation between PGs concentration in semen and the degree of fertility has been demonstrated (4) . Based on experimental studies, PGs have had an inhibitory effect on testicular steroidgensis (5) , and spermatogenesis in vivo (6) , and on sperm motility in vitro (7) . These observations agree with the deleterious effects of PGs on fertility pontential and suggest the possible effective role of prostaglandin synthetase inhibitors in treated subfertile men.
(8)
The present study aimed at shedding a light on the role of a prostaglandin synthetase inhibitor, namely indomethacin, on fertility and sperm quality among oligospermic patients as well as its effect in changing the plasma levels of luteinzing hormone (LH), follicular stimulating hormone (FSH) and testosterone (T) in the same patients.
SUBJECTS & METHODS
Twenty oligospermic individuals having the age range from 20-35 years, with a sperm count of 1×10 6 to 19× 10 6 /ml and sperm motility less than 60% were included in the study. The duration of their infertility ranged from 2 to 4 years (mean = 2.8 year) despite of their regular sexual contact with their wives and despite of the fact that their wives had normal biphasic cycles with ovulation and their hormonal pattern and hysterosalpingiography were normal. None of these oligospermic patients had received hormonal therapy (e.g. anti-oestrogen or androgens) or any drugs affecting spermatogenesis (9) , (e.g. caffeine, thyroxine, sulphasalazine, spironolactone .. etc.) during the last three months before their participation on the present study. Smokers were excluded.
Indomoethacin was taken at a dose of 25mg, after meal, three times a day for three months (90 days).
Seminal prostaglandin E (PGE) level was estimated by radio-immuno assay using Radioimmuno-assay kit (RIA), Cataglo No 8-6223, lot 401248, advanced magnetics incorporation (16-Money street, Cambridge, MA 02138, U.K).
Control group (20 patients) with the same experimental conditions received 50mg sucrose in capsules orally BID as placebo served as control group. This group was subjected to the same above mentional laboratory procedures.
RESULTS
Results were evaluated using paired "t" test.
(10)
Patients receiving indomethacin showed: -A statistically significant (P<0.05) increase in sperm count and motility in semen specimens obtained on day 90 was reported as compared to the same parameters in semen samples obtained on day 0 (Table  1 ). The pregnancy rate among which was 15% (3 out of 20). -A statistically significant (P<0.05)
higher mean plasma testosterone (T) levels on day 90, than the mean plasma (T) levels in blood specimens obtained on day 0. (Table 2 ). -A rather statistically insignificant difference in plasma FSH & LH levels in specimens obtained on day 90 compared to their corresponding level in day 0. (Table 2) . N.S.: Non Significant.
-A statistically significant (P<0.05) higher seminal PGE levels in semen samples obtained from patients at the start of therapy (day 0), than the corresponding levels in semen samples obtained on day 90 (Table 3) . 
Subjects receiving placebo (control group):
Throughout the whole period of experiment, constant values were reported in hormone levels in plasma specimens, in sperm quality, motility and in PGE levels in semen in specimens obtained on day 0 and day 90. Due to the bell-shaped curve of activity of prostaglandins.
(13) Such as inhibitory on body metabolic processes and spermatogenesis at high concentrations, the inhibitory effect of PGs on testicular function and sperm motility would be an underlying cause in some infertile men. Thus, a question would be raised as to whether or not the suppression of PGs synthesis with the help of an arsenal of non-steroidal anti-inflammatory drugs could be a line of therapy to improve sperm quality and fertility in men.
In the present study a daily dose of oral indomethacin (75mg/day), given for 90 days to encompass the process of spermatogenesis, induced insignificant change in serum FSH and LH levels and a statistically significant (P<0.05) rise in serum testosterone with improvement of sperm count and sperm motility together with a pregnancy rate of 15% (3of 20) as compared to the corresponding levels and sperm parameters in the same patients before indomathacin administration.
Similarly, a statistically significant (P<0.05) lower seminal plasma PGE on day 90, than PGE level on day 0 before the drug intake was shown. As much as placebo therapy could not induce any change in these parameters, when used for 90 days, among placebo group it could be postulated that indomethacin improved fertility potential among these patients. The drug in question could have acted via different mechanisms.
(5-14-15) Indomethacin might act on hypothalamic -pituitary axis affecting both FSH & LH levels hence testosterone level. The drug could additionally suppress estrogen formation by leydig cells in some oligospermic men. Moreover, indomethacin increases level of seminal plasma cyclic adenosine monophosphate (cAMP), thus promoting sperm motility.
(18-19) These results go with the effective action of indomethacin in treating some oligospermic patients and was confirmed by an earlier report of 
Barlke et al.
(6) and Rolf et al. (20) in a controlled study examined the effect of indomethacin (75mg/day for 60 days on 100 oligospermic patients).
They observed an increase in both FSH & LH with a simultaneous droppage of testosterone level, and decrease in PGs' concentrations in seminal plasma. Also, there was a significant increase in both sperm count and motility. Barkay et al.,
, and Ombelet et al., (21) 
